Novatim Immune Therapeutics (Zhejiang) Co., Ltd. announced a landmark exclusive licensing collaboration with RADIANCE Biopharma. Under the agreement, Novatim grants Radiance the rights to develop, register, and commercialize KY‑0301—a first‑in‑class nano‑bispecific antibody‑drug conjugate (ADC)—outside of China.
Deal Structure
| Component | Value | Notes |
|---|---|---|
| Upfront Payment | $15 million | Immediate cash to Novatim |
| Development & Regulatory Milestones | Up to $150 million | Triggered upon completion of key study milestones |
| Commercial Milestones | Up to $1 billion | Based on sales thresholds in licensed territories |
| Royalties | Tiered | Percentage of annual net sales, scaling with volume |
KY‑0301: A Breakthrough Nano‑Bispecific ADC
- Dual Targeting – Simultaneously engages EGFR and c‑MET, two drivers of tumor progression in solid cancers.
- Nano‑Delivery Platform – Uses a nano‑size conjugate to improve tumor penetration while reducing systemic exposure, thereby lowering off‑target toxicity.
- Safety Profile – Preclinical data show a markedly better safety margin compared with existing bispecific ADCs, with fewer infusion reactions and reduced hematologic toxicity.
- Clinical Status – Received U.S. IND approval in 2024. Currently in a Phase I dose‑escalation trial in China, demonstrating superior tumor penetration and anti‑tumor activity.
Strategic Implications
- Accelerated Global Reach – RADIANCE will lead development and commercialization worldwide, leveraging its established oncology pipeline and regulatory experience.
- Revenue Upside for Novatim – The multi‑tiered milestone structure and royalty program position Novatim for significant cash flow once KY‑0301 enters the market.
- Innovation Leadership – The collaboration underscores Novatim’s commitment to pioneering nano‑bispecific ADCs and expands RADIANCE’s portfolio in the rapidly evolving ADC space.-Fineline Info & Tech
